MicroRNAs in Cholangiopathies

Current Pathobiology Reports

Volumn 2, Issue 3, 2014, Pages 133-142

  O’Hara, Steven P ^a   Gradilone, Sergio A ^a   Masyuk, Tetyana V ^a   Tabibian, James H ^a   LaRusso, Nicholas F ^a  

^a MAYO CLINIC   (United States)

Author keywords

Biliary atresia; Cholangiocarcinoma; Cholangiocytes; MicroRNAs, cholangiopathies; Polycystic liver disease; Primary biliary cirrhosis; Primary sclerosing cholangitis

Indexed keywords

EID: 84928539225     PISSN: None     EISSN: 2167485X     Source Type: Journal    
DOI: 10.1007/s40139-014-0048-9     Document Type: Review

References (87)

1. Lazaridis KN, Strazzabosco M, Larusso NF (2004) The cholangiopathies: disorders of biliary epithelia. Gastroenterology 127:1565–1577
2. Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136:215–233
3. Garzon R, Marcucci G, Croce CM (2010) Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 9:775–789
4. Razumilava N, Gores GJ (2014) Cholangiocarcinoma. Lancet. doi:10.1016/S0140-6736(13)61903-0
5. Munoz-Garrido P, Garcia-Fernandez de Barrena M, Hijona E, Carracedo M, Marin JJ, Bujanda L, Banales JM (2012) MicroRNAs in biliary diseases. World J Gastroenterol 18:6189–6196
6. Natarajan SK, Smith MA, Wehrkamp CJ, Mohr AM, Mott JL (2013) MicroRNA function in human diseases. Med Epigenetic 1:106–115
7. Qiu YH, Wei YP, Shen NJ, Wang ZC, Kan T, Yu WL, Yi B, Zhang YJ (2013) miR-204 inhibits epithelial to mesenchymal transition by targeting slug in intrahepatic cholangiocarcinoma cells. Cell Physiol Biochem 32:1331–1341
8. Li B, Han Q, Zhu Y, Yu Y, Wang J, Jiang X (2012) Down-regulation of miR-214 contributes to intrahepatic cholangiocarcinoma metastasis by targeting Twist. FEBS J 279:2393–2398
9. Peng F, Jiang J, Yu Y, Tian R, Guo X, Li X, Shen M, Xu M, Zhu F, Shi C, Hu J, Wang M, Qin R (2013) Direct targeting of SUZ12/ROCK2 by miR-200b/c inhibits cholangiocarcinoma tumourigenesis and metastasis. Br J Cancer 109:3092–3104
10. Iliopoulos D, Lindahl-Allen M, Polytarchou C, Hirsch HA, Tsichlis PN, Struhl K (2010) Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol Cell 39:761–772
11. •• Okamoto K, Miyoshi K, Murawaki Y (2013) miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells. PLoS One 8:e77623. MicroRNA expression profiling of a gemcitabine resistant cell line (HuH28) vs. a sensitive cell line (HuCCT1) revealed three downregulated microRNAs and one upregulated microRNA associated with chemotherapeutic resistance.
12. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, Jiang J, Schmittgen TD, Patel T (2006) Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 130:2113–2129
13. Iwaki J, Kikuchi K, Mizuguchi Y, Kawahigashi Y, Yoshida H, Uchida E, Takizawa T (2013) MiR-376c down-regulation accelerates EGF-dependent migration by targeting GRB2 in the HuCCT1 human intrahepatic cholangiocarcinoma cell line. PLoS One 8:e69496
14. Wang Q, Tang H, Yin S, Dong C (2013) Downregulation of microRNA-138 enhances the proliferation, migration and invasion of cholangiocarcinoma cells through the upregulation of RhoC/p-ERK/MMP-2/MMP-9. Oncol Rep 29:2046–2052
15. Hu C, Huang F, Deng G, Nie W, Huang W, Zeng X (2013) miR-31 promotes oncogenesis in intrahepatic cholangiocarcinoma cells via the direct suppression of RASA1. Exp Ther Med 6:1265–1270
16. Zeng B, Li Z, Chen R, Guo N, Zhou J, Zhou Q, Lin Q, Cheng D, Liao Q, Zheng L, Gong Y (2012) Epigenetic regulation of miR-124 by hepatitis C virus core protein promotes migration and invasion of intrahepatic cholangiocarcinoma cells by targeting SMYD3. FEBS Lett 586:3271–3278
17. Lu L, Byrnes K, Han C, Wang Y, Wu T (2014) MiR-21 targets 15-PGDH and promotes cholangiocarcinoma growth. Mol Cancer Res. doi:10.1158/1541-7786
18. Chusorn P, Namwat N, Loilome W, Techasen A, Pairojkul C, Khuntikeo N, Dechakhamphu A, Talabnin C, Chan-On W, Ong CK, Teh BT, Yongvanit P (2013) Overexpression of microRNA-21 regulating PDCD4 during tumorigenesis of liver fluke-associated cholangiocarcinoma contributes to tumor growth and metastasis. Tumour Biol 34:1579–1588
19. Chandok N (2012) Polycystic liver disease: a clinical review. Ann Hepatol 11:819–826
20. Gevers TJ, Drenth JP (2013) Diagnosis and management of polycystic liver disease. Nat Rev Gastroenterol Hepatol 10(2):101–108
21. Masyuk T, Masyuk A, Larusso N (2009) Cholangiociliopathies: genetics, molecular mechanisms and potential therapies. Curr Opin Gastroenterol 25:265–271
22. Bhatt K, Mi QS, Dong Z (2011) microRNAs in kidneys: biogenesis, regulation, and pathophysiological roles. Am J Physiol Renal Physiol 300:F602–F610
23. Lee SO, Masyuk T, Splinter P, Banales JM, Masyuk A, Stroope A, Larusso N (2008) MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease. J Clin Invest 118:3714–3724
24. Masyuk T, Masyuk A, Larusso N (2009) MicroRNAs in cholangiociliopathies. Cell Cycle 8:1324–1328
25. Pandey P, Brors B, Srivastava PK, Bott A, Boehn SN, Groene HJ, Gretz N (2008) Microarray-based approach identifies microRNAs and their target functional patterns in polycystic kidney disease. BMC Genomics 9:624
26. Park EY, Woo YM, Park JH (2011) Polycystic kidney disease and therapeutic approaches. BMB Rep 44:359–368
27. Wills ES, Roepman R, Drenth JP (2014) Polycystic liver disease: ductal plate malformation and the primary cilium. Trends Mol Med 20:261–270
28. Strazzabosco M, Somlo S (2011) Polycystic liver diseases: congenital disorders of cholangiocyte signaling. Gastroenterology 140:1855–1859, 1859 e1851.
29. Sun H, Li QW, Lv XY, Ai JZ, Yang QT, Duan JJ, Bian GH, Xiao Y, Wang YD, Zhang Z, Liu YH, Tan RZ, Yang Y, Wei YQ, Zhou Q (2010) MicroRNA-17 post-transcriptionally regulates polycystic kidney disease-2 gene and promotes cell proliferation. Mol Biol Rep 37:2951–2958
30. Tran U, Zakin L, Schweickert A, Agrawal R, Doger R, Blum M, De Robertis EM, Wessely O (2010) The RNA-binding protein bicaudal C regulates polycystin 2 in the kidney by antagonizing miR-17 activity. Development 137:1107–1116
31. Wang E, Hsieh-Li HM, Chiou YY, Chien YL, Ho HH, Chin HJ, Wang CK, Liang SC, Jiang ST (2010) Progressive renal distortion by multiple cysts in transgenic mice expressing artificial microRNAs against Pkd1. J Pathol 222:238–248
32. Schena FP, Serino G, Sallustio F (2014) MicroRNAs in kidney diseases: new promising biomarkers for diagnosis and monitoring. Nephrol Dial Transplant 29:755–763
33. Raynaud P, Carpentier R, Antoniou A, Lemaigre FP (2011) Biliary differentiation and bile duct morphogenesis in development and disease. Int J Biochem Cell Biol 43:245–256
34. Temmerman F, Missiaen L, Bammens B, Laleman W, Cassiman D, Verslype C, van Pelt J, Nevens F (2011) Systematic review: the pathophysiology and management of polycystic liver disease. Aliment Pharmacol Ther 34:702–713
35. Gunay-Aygun M (2009) Liver and kidney disease in ciliopathies. Am J Med Genet C Semin Med Genet 151C:296–306
36. Desmet VJ (1998) Ludwig symposium on biliary disorders: part I. Pathogenesis of ductal plate abnormalities. Mayo Clin Proc 73:80–89
37. Decaens T, Godard C, de Reynies A, Rickman DS, Tronche F, Couty JP, Perret C, Colnot S (2008) Stabilization of beta-catenin affects mouse embryonic liver growth and hepatoblast fate. Hepatology 47:247–258
38. Raynaud P, Tate J, Callens C, Cordi S, Vandersmissen P, Carpentier R, Sempoux C, Devuyst O, Pierreux CE, Courtoy P, Dahan K, Delbecque K, Lepreux S, Pontoglio M, Guay-Woodford LM, Lemaigre FP (2011) A classification of ductal plate malformations based on distinct pathogenic mechanisms of biliary dysmorphogenesis. Hepatology 53:1959–1966
39. May-Simera HL, Kelley MW (2012) Cilia, Wnt signaling, and the cytoskeleton. Cilia 1:7
40. Benzing T, Simons M, Walz G (2007) Wnt signaling in polycystic kidney disease. J Am Soc Nephrol 18:1389–1398
41. Neugebauer JM, Amack JD, Peterson AG, Bisgrove BW, Yost HJ (2009) FGF signalling during embryo development regulates cilia length in diverse epithelia. Nature 458:651–654
42. Hand NJ, Master ZR, Eauclaire SF, Weinblatt DE, Matthews RP, Friedman JR (2009) The microRNA-30 family is required for vertebrate hepatobiliary development. Gastroenterology 136:1081–1090
43. Sokol RJ, Shepherd RW, Superina R, Bezerra JA, Robuck P, Hoofnagle JH (2007) Screening and outcomes in biliary atresia: summary of a National Institutes of Health workshop. Hepatology 46:566–581
44. • Padgett KA, Lan RY, Leung PC, Lleo A, Dawson K, Pfeiff J, Mao TK, Coppel RL, Ansari AA, Gershwin ME (2009) Primary biliary cirrhosis is associated with altered hepatic microRNA expression. J Autoimmun 32:246–253. This is the first report of microRNA expression analyses used to identify dysregulated microRNAs and PBC.
45. Medina JF, Martinez A, Vazquez JJ, Prieto J (1997) Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis. Hepatology 25:12–17
46. Melero S, Spirli C, Zsembery A, Medina JF, Joplin RE, Duner E, Zuin M, Neuberger JM, Prieto J, Strazzabosco M (2002) Defective regulation of cholangiocyte Cl-/HCO3(-) and Na +/H + exchanger activities in primary biliary cirrhosis. Hepatology 35:1513–1521
47. Banales JM, Arenas F, Rodriguez-Ortigosa CM, Saez E, Uriarte I, Doctor RB, Prieto J, Medina JF (2006) Bicarbonate-rich choleresis induced by secretin in normal rat is taurocholate-dependent and involves AE2 anion exchanger. Hepatology 43:266–275
48. Banales JM, Prieto J, Medina JF (2006) Cholangiocyte anion exchange and biliary bicarbonate excretion. World J Gastroenterol 12:3496–3511
49. 3 - anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis. Hepatology 56:687–697. Determined that the upregulated microRNA, miR-506, targeted the chloride/bicarbonate exchanger, AE2, in PBC cholangiocytes; and suppression of miR-506 in isolated PBC cholangiocytes improves AE2 activity.
50. Qin B, Huang F, Liang Y, Yang Z, Zhong R (2013) Analysis of altered microRNA expression profiles in peripheral blood mononuclear cells from patients with primary biliary cirrhosis. J Gastroenterol Hepatol 28:543–550
51. Ninomiya M, Kondo Y, Funayama R, Nagashima T, Kogure T, Kakazu E, Kimura O, Ueno Y, Nakayama K, Shimosegawa T (2013) Distinct microRNAs expression profile in primary biliary cirrhosis and evaluation of miR 505-3p and miR197-3p as novel biomarkers. PLoS One 8:e66086
52. Aron JH, Bowlus CL (2009) The immunobiology of primary sclerosing cholangitis. Semin Immunopathol 31:383–397
53. Wiesner RH, Grambsch PM, Dickson ER, Ludwig J, MacCarty RL, Hunter EB, Fleming TR, Fisher LD, Beaver SJ, LaRusso NF (1989) Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology 10:430–436
54. Bergquist A, Ekbom A, Olsson R, Kornfeldt D, Loof L, Danielsson A, Hultcrantz R, Lindgren S, Prytz H, Sandberg-Gertzen H, Almer S, Granath F, Broome U (2002) Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 36:321–327
55. Boberg KM, Bergquist A, Mitchell S, Pares A, Rosina F, Broome U, Chapman R, Fausa O, Egeland T, Rocca G, Schrumpf E (2002) Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol 37:1205–1211
56. •• Li L, Masica D, Ishida M, Tomuleasa C, Umegaki S, Kalloo AN, Georgiades C, Singh VK, Khashab M, Amateau S, Li Z, Okolo P, Lennon AM, Saxena P, Geschwind JF, Schlachter T, Hong K, Pawlik TM, Canto M, Law J, Sharaiha R, Weiss CR, Thuluvath P, Goggins M, Shin EJ, Peng H, Kumbhari V, Hutfless S, Zhou L, Mezey E, Meltzer SJ, Karchin R, Selaru FM (2014) Human bile contains microRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis. Hepatology. This study is the first to demonstrate that microRNAs from biliary exosomes hold great promise as diagnostic tools for CCA; a novel bile-based CCA diagnostic microRNA panel is presented.
57. Shigehara K, Yokomuro S, Ishibashi O, Mizuguchi Y, Arima Y, Kawahigashi Y, Kanda T, Akagi I, Tajiri T, Yoshida H, Takizawa T, Uchida E (2011) Real-time PCR-based analysis of the human bile microRNAome identifies miR-9 as a potential diagnostic biomarker for biliary tract cancer. PLoS One 6:e23584
58. Hartley JL, Davenport M, Kelly DA (2009) Biliary atresia. Lancet 374:1704–1713
59. Bezerra JA (2005) Potential etiologies of biliary atresia. Pediatr Transplant 9:646–651
60. • Hand NJ, Horner AM, Master ZR, Boateng LA, LeGuen C, Uvaydova M, Friedman JR (2012) MicroRNA profiling identifies miR-29 as a regulator of disease-associated pathways in experimental biliary atresia. J Pediatr Gastroenterol Nutr 54:186–192. A family of microRNAs dysregulated in the RRV model of BA was identified. Moreover, in vivo suppression of miR-29, using intraperitoneal injection of antisense oligonucleotides, resulted in a concomitant increase in predicted targets of this microRNA.
61. Roderburg C, Urban GW, Bettermann K, Vucur M, Zimmermann H, Schmidt S, Janssen J, Koppe C, Knolle P, Castoldi M, Tacke F, Trautwein C, Luedde T (2011) Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology 53:209–218
62. •• Bessho K, Shanmukhappa K, Sheridan R, Shivakumar P, Mourya R, Walters S, Kaimal V, Dilbone E, Jegga AG, Bezerra JA (2013) Integrative genomics identifies candidate microRNAs for pathogenesis of experimental biliary atresia. BMC Syst Biol 7:104. An integrative genomics approach was used to reveal potential functional relevance of microRNAs and predicted targets in biliary atresia; provides information for further diagnostic and pathogenesis research.
63. Carvalho E, Liu C, Shivakumar P, Sabla G, Aronow B, Bezerra JA (2005) Analysis of the biliary transcriptome in experimental biliary atresia. Gastroenterology 129:713–717
64. Olnes MJ, Erlich R (2004) A review and update on cholangiocarcinoma. Oncology 66:167–179
65. Tabibian JH, Lindor KD (2012) Challenges of cholangiocarcinoma detection in patients with primary sclerosing cholangitis. J Anal Oncol 1:50–55
66. Lazaridis KN, Gores GJ (2006) Primary sclerosing cholangitis and cholangiocarcinoma. Semin Liver Dis 26:42–51
67. Aljiffry M, Walsh MJ, Molinari M (2009) Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990–2009. World J Gastroenterol 15:4240–4262
68. Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Thursz MR, Wasan H (2002) Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 51(Suppl 6):VI1-9.
69. • McNally ME, Collins A, Wojcik SE, Liu J, Henry JC, Jiang J, Schmittgen T, Bloomston M (2013) Concomitant dysregulation of microRNAs miR-151-3p and miR-126 correlates with improved survival in resected cholangiocarcinoma. HPB (Oxford) 15:260–264. The authors demonstrated the prognostic value of two microRNAs form CCA tissues.
70. Huang Q, Liu L, Liu CH, You H, Shao F, Xie F, Lin XS, Hu SY, Zhang CH (2013) MicroRNA-21 regulates the invasion and metastasis in cholangiocarcinoma and may be a potential biomarker for cancer prognosis. Asian Pac J Cancer Prev 14:829–834
71. Zahm AM, Hand NJ, Boateng LA, Friedman JR (2012) Circulating microRNA is a biomarker of biliary atresia. J Pediatr Gastroenterol Nutr 55:366–369
72. Krutzfeldt J, Kuwajima S, Braich R, Rajeev KG, Pena J, Tuschl T, Manoharan M, Stoffel M (2007) Specificity, duplex degradation and subcellular localization of antagomirs. Nucleic Acids Res 35:2885–2892
73. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, Stoffel M (2005) Silencing of microRNAs in vivo with ‘antagomirs’. Nature 438:685–689
74. Zhang Y, Wang Z, Gemeinhart RA (2013) Progress in microRNA delivery. J Control Release 172:962–974
75. Meng F, Henson R, Wehbe-Janek H, Smith H, Ueno Y, Patel T (2007) The MicroRNA let-7a modulates interleukin-6-dependent STAT-3 survival signaling in malignant human cholangiocytes. J Biol Chem 282:8256–8264
76. He Q, Cai L, Shuai L, Li D, Wang C, Liu Y, Li X, Li Z, Wang S (2013) Ars2 is overexpressed in human cholangiocarcinomas and its depletion increases PTEN and PDCD4 by decreasing MicroRNA-21. Mol Carcinog 52:286–296
77. Selaru FM, Olaru AV, Kan T, David S, Cheng Y, Mori Y, Yang J, Paun B, Jin Z, Agarwal R, Hamilton JP, Abraham J, Georgiades C, Alvarez H, Vivekanandan P, Yu W, Maitra A, Torbenson M, Thuluvath PJ, Gores GJ, LaRusso NF, Hruban R, Meltzer SJ (2009) MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology 49:1595–1601
78. Razumilava N, Bronk SF, Smoot RL, Fingas CD, Werneburg NW, Roberts LR, Mott JL (2012) miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma. Hepatology 55:465–475
79. Zhang J, Han C, Wu T (2012) MicroRNA-26a promotes cholangiocarcinoma growth by activating beta-catenin. Gastroenterology 143(246–256):e248
80. Yang H, Li TW, Peng J, Tang X, Ko KS, Xia M, Aller MA (2011) A mouse model of cholestasis-associated cholangiocarcinoma and transcription factors involved in progression. Gastroenterology 141:378–388, 388 e371–374.
81. Zhong XY, Yu JH, Zhang WG, Wang ZD, Dong Q, Tai S, Cui YF, Li H (2012) MicroRNA-421 functions as an oncogenic miRNA in biliary tract cancer through down-regulating farnesoid X receptor expression. Gene 493:44–51
82. Braconi C, Huang N, Patel T (2010) MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology 51:881–890
83. Chen L, Yan HX, Yang W, Hu L, Yu LX, Liu Q, Li L, Huang DD, Ding J, Shen F, Zhou WP, Wu MC, Wang HY (2009) The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma. J Hepatol 50:358–369
84. Meng F, Wehbe-Janek H, Henson R, Smith H, Patel T (2008) Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes. Oncogene 27:378–386
85. Chen Y, Luo J, Tian R, Sun H, Zou S (2011) miR-373 negatively regulates methyl-CpG-binding domain protein 2 (MBD2) in hilar cholangiocarcinoma. Dig Dis Sci 56:1693–1701
86. Olaru AV, Ghiaur G, Yamanaka S, Luvsanjav D, An F, Popescu I, Alexandrescu S, Allen S, Pawlik TM, Torbenson M, Georgiades C, Roberts LR, Gores GJ, Ferguson-Smith A, Almeida MI, Calin GA, Mezey E, Selaru FM (2011) MicroRNA down-regulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S checkpoint. Hepatology 54:2089–2098
87. Mott JL, Kobayashi S, Bronk SF, Gores GJ (2007) mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 26:6133–6140